Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets: A novel mechanism enhancing platelet activity in hypercholesterolemia

Circulation

Volumn 95, Issue 6, 1997, Pages 1370-1377

  Nofer, Jerzy Roch ^a   Tepel, Martin ^b   Kehrel, Beate ^c   Wierwille, Sonja ^c   Walter, Michael ^a   Seedorf, Udo ^a   Zidek, Walter ^b   Assmann, Gerd ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Inn Med A   (Germany)

Author keywords

hypercholesterolemia; lipoproteins; platelets

Indexed keywords

(3 METHYLSULFONYL 4 PIPERIDINOBENZOYL)GUANIDINE METHANESULFONATE; FIBRINOGEN RECEPTOR; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLINOSITIDE; THROMBIN;

ADULT; ARTICLE; ATHEROGENESIS; BINDING SITE; CELL PH; CLINICAL ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTON SODIUM EXCHANGE; THROMBOCYTE FUNCTION;

EID: 0030971411     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.6.1370     Document Type: Article

References (12)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993:362:801-809.
2. Surya I, Akkerman J-W. The influence of lipoproteins on blood platelets. Am Heart J. 1993;125:272-275.
3. Joist JH, Baker RK, Schonfeld G. Increased in vivo and in vitro platelet function in type II- and type IV-hyperlipoproteinemia. Thromb Res. 1979;15:95-108.
4. Beitz J, Block HU, Beitz A, Muller G, Winkler L, Dargel R, Mest HJ. Endogenous lipoproteins modify the thromboxane formation capacity of platelets. Atherosclerosis. 1986;60:95-99.
5. Andrews HE, Aitken JW, Hassal DG, Skinner VO, Bruckdorfer KR. Intracellular mechanisms in the activation of human platelets by low-density lipoproteins. Biochem J. 1987;242:559-564.
6. Block LH, Knorr M, Vogt E, Locher R, Vetter W, Groscurth P, Qiao BY, Pometta D, James R, Regenass M, Pletscher A. Low density lipoprotein causes general cellular activation with increased phosphatidylinositol turnover and lipoprotein catabolism. Proc Natl Acad Sci USA. 1988;85:885-889.
7. Siffert W. Regulation of platelet function by sodium-hydrogen exchange. Cardiovasc Res. 1995;29:160-166.
8. + antiporter isoforms using amiloride analogs and a new inhibitor exhibiting anti-ischemic properties. Mol Pharmacol. 1993;44:1041-1045.
9. Nofer J-R, Walter M, Seedorf U, Assmann G. HDL3 activates phospholipase D in normal but not in glycoprotein IIb/IIIa-deficient platelets. Biochem Biophys Res Commun. 1995;207:148-154.
10. Kehrel B, Kronenberg A, Rauterberg J, Niesing-Bresch D, Niehues U, Kardoeus J, Schwippert B, Tschöpe D, van de Loo J, Clemetson KJ. Platelets deficient in glycoprotein IIIb aggregate normally to collagens type I and III but not to collagen type V. Blood. 1993;83:3364-3370.
11. + antiport in human platelets. Thromb Haemost. 1996;75:635-641.
12. Havel RJ, Eder H, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955:3:1345-1353.